Journal: Journal of Clinical Medicine

Article Title: Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ

doi: 10.3390/jcm13164799

Figure Lengend Snippet: The frequency of BRAF mutations varies across diagnoses.

Article Snippet: Three reaction mixtures were prepared for each sample: (i) mix with Mutation Detection Assay for V600E mutation (BRAF_476_mu; Assay ID: Hs00000111_mu), (ii) mix with Mutation Detection Assay for V600K mutation (BRAF_473_mu; Assay ID: Hs00000769_mu), (iii) Reference Assay (BRAF_rf; Assay ID: Hs00000172_rf).

Techniques: Mutagenesis

Journal: Journal of Clinical Medicine

Article Title: Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ

doi: 10.3390/jcm13164799

Figure Lengend Snippet: Presence and frequency of BRAF mutation between patients with ND, MIS, and LM.

Article Snippet: Three reaction mixtures were prepared for each sample: (i) mix with Mutation Detection Assay for V600E mutation (BRAF_476_mu; Assay ID: Hs00000111_mu), (ii) mix with Mutation Detection Assay for V600K mutation (BRAF_473_mu; Assay ID: Hs00000769_mu), (iii) Reference Assay (BRAF_rf; Assay ID: Hs00000172_rf).

Techniques: Mutagenesis

Journal: Journal of Clinical Medicine

Article Title: Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ

doi: 10.3390/jcm13164799

Figure Lengend Snippet: Age distribution of patients with and without BRAF mutation.

Article Snippet: Three reaction mixtures were prepared for each sample: (i) mix with Mutation Detection Assay for V600E mutation (BRAF_476_mu; Assay ID: Hs00000111_mu), (ii) mix with Mutation Detection Assay for V600K mutation (BRAF_473_mu; Assay ID: Hs00000769_mu), (iii) Reference Assay (BRAF_rf; Assay ID: Hs00000172_rf).

Techniques: Mutagenesis

Journal: Journal of Clinical Medicine

Article Title: Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ

doi: 10.3390/jcm13164799

Figure Lengend Snippet: Correlation of BRAF mutation and localization.

Article Snippet: Three reaction mixtures were prepared for each sample: (i) mix with Mutation Detection Assay for V600E mutation (BRAF_476_mu; Assay ID: Hs00000111_mu), (ii) mix with Mutation Detection Assay for V600K mutation (BRAF_473_mu; Assay ID: Hs00000769_mu), (iii) Reference Assay (BRAF_rf; Assay ID: Hs00000172_rf).

Techniques: Mutagenesis

Journal: Journal of Clinical Medicine

Article Title: Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ

doi: 10.3390/jcm13164799

Figure Lengend Snippet: Tumor size distribution in patients with and without BRAF mutation. ∗ and ◦ represent outliers.

Article Snippet: Three reaction mixtures were prepared for each sample: (i) mix with Mutation Detection Assay for V600E mutation (BRAF_476_mu; Assay ID: Hs00000111_mu), (ii) mix with Mutation Detection Assay for V600K mutation (BRAF_473_mu; Assay ID: Hs00000769_mu), (iii) Reference Assay (BRAF_rf; Assay ID: Hs00000172_rf).

Techniques: Mutagenesis

Journal: Journal of Clinical Medicine

Article Title: Frequency of BRAF Mutations in Dysplastic Nevi, Lentigo Maligna, and Melanoma In Situ

doi: 10.3390/jcm13164799

Figure Lengend Snippet: Correlation between the presence of the BRAF mutation and a previous melanoma diagnosis.

Article Snippet: Three reaction mixtures were prepared for each sample: (i) mix with Mutation Detection Assay for V600E mutation (BRAF_476_mu; Assay ID: Hs00000111_mu), (ii) mix with Mutation Detection Assay for V600K mutation (BRAF_473_mu; Assay ID: Hs00000769_mu), (iii) Reference Assay (BRAF_rf; Assay ID: Hs00000172_rf).

Techniques: Mutagenesis, Biomarker Discovery

Journal: Oncotarget

Article Title: Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity

doi: 10.18632/oncotarget.27891

Figure Lengend Snippet: Clinical and molecular features of control samples

Article Snippet: Detection and measurement of BRAF V600E (BRAF_476_mu: Hs00000111_mu; BRAF_rf: Hs00000172_rf), HRAS G12D (HRAS_484_mu: Hs00000778_mu; HRAS_ref: Hs00001018_rf), HRAS Q61K (HRAS_496_mu: Hs00000785_mu; HRAS_ref: Hs00001018_rf), HRAS Q61L (HRAS_498_mu: Hs00000786_mu; HRAS_ref: Hs00001018_rf) and KRAS G12D (KRAS_521_mu: Hs00000121_mu; KRAS_rf: Hs00000174_rf) somatic mutations was done by means of competitive allele-specific TaqManTM PCR technology (castPCRTM Technology).

Techniques: Control

Journal: Oncology Letters

Article Title: Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma

doi: 10.3892/ol.2017.7652

Figure Lengend Snippet: Patients with BRAF mutations (n=12).

Article Snippet: CastPCR Extracted DNA samples from FFPE tissues were analyzed by the following Taqman ® Mutation Detection Assay kits (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA): EGFR_reference (Catalog Number: 4465807, Assay ID: Hs00000173_rf) and BRAF_reference (Catalog Number: 4465807, Assay ID: Hs00000172_rf); EGFR_6223_mu (Catalog Number: 4465804, Assay ID: Hs00000156_mu), EGFR_6225_mu (Catalog Number: 4465804, Assay ID: Hs00000157_mu), EGFR_6224_mu (Catalog Number: 4465804, Assay ID: Hs00000102_mu) and EGFR_6240_mu (Catalog Number: 4465804, Assay ID: Hs00000106_mu) for detecting the 2235–2249 del, 2236–2250 del, L858R and T790M, respectively; BRAF_460_mu (Catalog Number: 4465804, Assay ID: Hs00001351_mu), BRAF_467_mu (Catalog Number: 4465804, Assay ID: Hs00000996_mu) and BRAF_475_mu (Catalog Number: 4465804, Assay ID: Hs00001384_mu) for detecting G469A, D594G and V600E, respectively.

Techniques: Mutagenesis

Journal: Oncology Letters

Article Title: Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma

doi: 10.3892/ol.2017.7652

Figure Lengend Snippet: Association between BRAF incidence and clinicopathological features.

Article Snippet: CastPCR Extracted DNA samples from FFPE tissues were analyzed by the following Taqman ® Mutation Detection Assay kits (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA): EGFR_reference (Catalog Number: 4465807, Assay ID: Hs00000173_rf) and BRAF_reference (Catalog Number: 4465807, Assay ID: Hs00000172_rf); EGFR_6223_mu (Catalog Number: 4465804, Assay ID: Hs00000156_mu), EGFR_6225_mu (Catalog Number: 4465804, Assay ID: Hs00000157_mu), EGFR_6224_mu (Catalog Number: 4465804, Assay ID: Hs00000102_mu) and EGFR_6240_mu (Catalog Number: 4465804, Assay ID: Hs00000106_mu) for detecting the 2235–2249 del, 2236–2250 del, L858R and T790M, respectively; BRAF_460_mu (Catalog Number: 4465804, Assay ID: Hs00001351_mu), BRAF_467_mu (Catalog Number: 4465804, Assay ID: Hs00000996_mu) and BRAF_475_mu (Catalog Number: 4465804, Assay ID: Hs00001384_mu) for detecting G469A, D594G and V600E, respectively.

Techniques:

Journal: Acta Medica Academica

Article Title: Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group

doi: 10.5644/ama2006-124.392

Figure Lengend Snippet: The List of FDA-Approved Companion Diagnostic and Authorized Tests/Assays for BRAF Testing [Adopted and Modified From ( 4 )].

Article Snippet: The THxID-BRAF kit (bioMerieux Inc.) , Malignant melanoma (covering V600E and V600K mutations) , Real-time PCR.

Techniques: Diagnostic Assay, Modification, Mutagenesis, Real-time Polymerase Chain Reaction

Journal: British Journal of Cancer

Article Title: Impact of KRAS , BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients

doi: 10.1038/s41416-021-01620-6

Figure Lengend Snippet: Characteristics of metastatic colorectal cancer patients with radical treatment (CRS-HIPEC, n = 180) or palliative/ explorative treatment ( n = 77).

Article Snippet: DNA quality was measured with Nanodrop TM (ThermoFisher, Waltham, Massachusetts, U.S.) and analysed for mut KRAS in exons 2, 3 and 4 ( KRAS Mutation Analysis, Entrogen) and for BRAF (V600E/K/D mutations) investigated with allele-specific real-time PCR (in-house setup, protocol available on request).

Techniques:

Journal: British Journal of Cancer

Article Title: Impact of KRAS , BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients

doi: 10.1038/s41416-021-01620-6

Figure Lengend Snippet: Tumour mutation analysis ( KRAS / BRAF ) in metastatic colorectal cancer patients with cytoreductive surgery and HIPEC (CRS-HIPEC) ( n = 174).

Article Snippet: DNA quality was measured with Nanodrop TM (ThermoFisher, Waltham, Massachusetts, U.S.) and analysed for mut KRAS in exons 2, 3 and 4 ( KRAS Mutation Analysis, Entrogen) and for BRAF (V600E/K/D mutations) investigated with allele-specific real-time PCR (in-house setup, protocol available on request).

Techniques: Mutagenesis

Journal: British Journal of Cancer

Article Title: Impact of KRAS , BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients

doi: 10.1038/s41416-021-01620-6

Figure Lengend Snippet: a Overall survival of CRS-HIPEC versus palliative surgery. The blue line represents the CRS-HIPEC group and the green dashed line represents the patients in the palliative group. Log-rank test shows a significant difference between the two groups with P < 0.001. b Overall survival comparing mutation status after palliative resection. Kaplan–Meier plot with time from surgery on the x axis and estimated overall survival on the y axis. The blue line represents the KRAS -mutated tumours (mut KRAS) tumours and the green dotted line represents the BRAF -mutated (mut BRAF) tumours. The gold dashed line represents the patients with KRAS and BRAF wild-type (double wt) tumours. Log-rank test shows a significant difference between the three groups with P < 0.001.

Article Snippet: DNA quality was measured with Nanodrop TM (ThermoFisher, Waltham, Massachusetts, U.S.) and analysed for mut KRAS in exons 2, 3 and 4 ( KRAS Mutation Analysis, Entrogen) and for BRAF (V600E/K/D mutations) investigated with allele-specific real-time PCR (in-house setup, protocol available on request).

Techniques: Mutagenesis

Journal: British Journal of Cancer

Article Title: Impact of KRAS , BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients

doi: 10.1038/s41416-021-01620-6

Figure Lengend Snippet: Survival of metastatic colorectal cancer patients after cytoreductive surgery and HIPEC according to mutational status in univariate analysis ( n = 174).

Article Snippet: DNA quality was measured with Nanodrop TM (ThermoFisher, Waltham, Massachusetts, U.S.) and analysed for mut KRAS in exons 2, 3 and 4 ( KRAS Mutation Analysis, Entrogen) and for BRAF (V600E/K/D mutations) investigated with allele-specific real-time PCR (in-house setup, protocol available on request).

Techniques:

Journal: British Journal of Cancer

Article Title: Impact of KRAS , BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients

doi: 10.1038/s41416-021-01620-6

Figure Lengend Snippet: a Overall survival after CRS-HIPEC based on mutation status. The blue line represents the KRAS -mutated tumours (mut KRAS) tumours and the green dotted line represents the BRAF -mutated (mut BRAF) tumours. The gold dashed line represents the patients with KRAS and BRAF wild-type (double wt) tumours. Log-rank test shows significant difference between mut BRAF vs mut KRAS , P = 0.046 and between mut BRAF vs double wt, P < 0.001. b Disease-free survival after CRS-HIPEC based on mutation status. Kaplan–Meier plot with time from surgery on the x axis and estimated overall survival on the y axis. The blue line represents the KRAS- mutated tumours (mut KRAS) and the green dotted line represents the BRAF -mutated (mut BRAF) tumours. The gold dashed line represents the patients with KRAS and BRAF wild-type (double wt) tumours. Log-rank test is ns. c Overall survival comparing mutation and microsatellite instability (MSI) status. Kaplan–Meier plot with time from surgery on the x axis and estimated overall survival on the y axis. The blue line represents the KRAS -mutated tumours (mut KRAS) tumours and the green dotted line represents the BRAF- mutated microsatellite stable (MSS) (mut BRAF /MSS) tumours. The gold dashed line represents the patients with KRAS and BRAF wild-type (double wt) tumours and the black dashed/dotted line represents the BRAF -mutated microsatellite instable (MSI (mut BRAF /MSI) tumours. Log-rank test shows a significant difference between mut BRAF groups with MSI or MSS with P = 0.022. d Disease-free survival after CRS-HIPEC based on mutation and microsatellite instability (MSI) status. Kaplan–Meier plot with time from surgery on the x axis and estimated overall survival on the y axis. The blue line represents the KRAS -mutated tumours (mut KRAS) tumours and the grey dotted line represents the BRAF -mutated microsatellite stable (MSS) (mut BRAF /MSS) tumours. The gold dashed line represents the patients with KRAS and BRAF wild-type (double wt) tumours and the black dashed/dotted line represents the BRAF -mutated microsatellite instable (MSI) (mut BRAF /MSI) tumours. Log-rank test shows a significant difference between mut BRAF /MSI group and mut KRAS group with P = 0.049.

Article Snippet: DNA quality was measured with Nanodrop TM (ThermoFisher, Waltham, Massachusetts, U.S.) and analysed for mut KRAS in exons 2, 3 and 4 ( KRAS Mutation Analysis, Entrogen) and for BRAF (V600E/K/D mutations) investigated with allele-specific real-time PCR (in-house setup, protocol available on request).

Techniques: Mutagenesis

Journal: British Journal of Cancer

Article Title: Impact of KRAS , BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients

doi: 10.1038/s41416-021-01620-6

Figure Lengend Snippet: Multivariable Cox regression analysis of OS and DFS after CRS-HIPEC in patients with PM-CRC ( n = 167).

Article Snippet: DNA quality was measured with Nanodrop TM (ThermoFisher, Waltham, Massachusetts, U.S.) and analysed for mut KRAS in exons 2, 3 and 4 ( KRAS Mutation Analysis, Entrogen) and for BRAF (V600E/K/D mutations) investigated with allele-specific real-time PCR (in-house setup, protocol available on request).

Techniques:

Journal: Epigenetics

Article Title: Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation

doi: 10.1080/15592294.2019.1580112

Figure Lengend Snippet: AQP1 transcript expression in tissues from the combined TCGA-COAD and TCGA-READ datasets by clinicopathological characteristics.

Article Snippet: For tissues, RNA sequencing expression (median number of fragments per kilobase of exon per million reads, FPKM), Infinium HumanMethylation450 BeadChip (HM450) DNA methylation (beta-values), and BRAF mutation data were obtained from TCGA Research Network ( http://cancergenome.nih.gov/ ).

Techniques: Expressing, Mutagenesis

Journal: Epigenetics

Article Title: Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation

doi: 10.1080/15592294.2019.1580112

Figure Lengend Snippet: Overall survival for the 453 patients with complete clinical data in the combined TCGA-COAD and TCGA-READ datasets.

Article Snippet: For tissues, RNA sequencing expression (median number of fragments per kilobase of exon per million reads, FPKM), Infinium HumanMethylation450 BeadChip (HM450) DNA methylation (beta-values), and BRAF mutation data were obtained from TCGA Research Network ( http://cancergenome.nih.gov/ ).

Techniques: Expressing, Mutagenesis

Journal: Frontiers in Oncology

Article Title: Clinicopathological correlations in 38 cases of gastroenteropancreatic high-grade neuroendocrine neoplasms

doi: 10.3389/fonc.2024.1399079

Figure Lengend Snippet: Illustrates the distribution of BRAF V600E mutation in GEP HG-NENs. A statistically significant disparity (**p=0.0086) was observed between NET G3 and SCNEC (A) . The distribution of KRAS mutation in GEP HG-NENs is also shown in the figure (B) .

Article Snippet: In our study, the BRAF V600E mutation was identified in 32.4% of the HG-NEN cases.

Techniques: Mutagenesis